Lotus Pharm (1795) reported revenue of NT$2.13 billion for Oct 2026, -22.5% year on year and -22.8% from the previous month. Revenue for Jan–Oct 2026 was NT$26.95 billion (+58.5% year on year).
In Oct 2026, it ranked No. 2 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$2.13 billion | -22.5% | -22.8% |
| Sep 2026 | NT$2.77 billion | +128.0% | +31.3% |
| Aug 2026 | NT$2.11 billion | +81.7% | -15.4% |
| Jul 2026 | NT$2.49 billion | +3.9% | -26.7% |
| Jun 2026 | NT$3.4 billion | +225.5% | +46.2% |
| May 2026 | NT$2.32 billion | +105.8% | -24.7% |
| Apr 2026 | NT$3.09 billion | +19.9% | -29.1% |
| Mar 2026 | NT$4.35 billion | +173.6% | +94.5% |
| Feb 2026 | NT$2.24 billion | +131.5% | +9.1% |
| Jan 2026 | NT$2.05 billion | -5.5% | -16.0% |
| Dec 2025 | NT$2.44 billion | +66.9% | +130.7% |
| Nov 2025 | NT$1.06 billion | -0.2% | -61.5% |
| Oct 2025 | NT$2.75 billion | +46.0% | +126.9% |
| Sep 2025 | NT$1.21 billion | +2.3% | +4.6% |
| Aug 2025 | NT$1.16 billion | -12.5% | -51.6% |
| Jul 2025 | NT$2.4 billion | -11.9% | +129.6% |
| Jun 2025 | NT$1.04 billion | -6.3% | -7.5% |
| May 2025 | NT$1.13 billion | -27.3% | -56.1% |
| Apr 2025 | NT$2.57 billion | +23.9% | +61.7% |
| Mar 2025 | NT$1.59 billion | +38.3% | +64.7% |
| Feb 2025 | NT$966.7 million | -8.1% | -55.5% |
| Jan 2025 | NT$2.17 billion | +8.8% | +48.4% |
| Dec 2024 | NT$1.46 billion | +6.6% | +38.0% |
| Nov 2024 | NT$1.06 billion | -6.6% | -43.7% |
| Oct 2024 | NT$1.88 billion | +106.8% | +58.8% |
Jan–Oct 2026 cumulative: NT$26.95 billion (+58.5% YoY)
Other Biotech & Medical companies
Compare with peers: Lotus Pharm vs PEC / Lotus Pharm vs Bora / Lotus Pharm vs Great Tree Pharmacy
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
| GKB | NT$748.3 million | -30.8% |
Company remark (original Chinese)
本年累計營收較去年同期增加主係受惠於併購NAGH後的營收挹注及出口業務成長所致。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16